
Coherus Oncology, Inc. (NASDAQ:CHRS – Free Report) – Stock analysts at HC Wainwright cut their FY2030 earnings per share estimates for Coherus Oncology in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn $0.15 per share for the year, down from their previous estimate of $0.19. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Coherus Oncology’s current full-year earnings is ($0.83) per share.
Coherus Oncology (NASDAQ:CHRS – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). The firm had revenue of $14.27 million for the quarter, compared to analysts’ expectations of $15.90 million. Coherus Oncology had a negative return on equity of 274.46% and a negative net margin of 253.43%.
A number of other brokerages also recently issued reports on CHRS. Weiss Ratings downgraded shares of Coherus Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 10th. Wall Street Zen cut shares of Coherus Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, November 14th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.
Read Our Latest Stock Analysis on Coherus Oncology
Coherus Oncology Stock Down 14.3%
CHRS opened at $0.41 on Thursday. The company has a debt-to-equity ratio of 2.08, a current ratio of 1.51 and a quick ratio of 1.45. The company’s 50-day moving average is $1.01 and its 200 day moving average is $1.45. Coherus Oncology has a fifty-two week low of $0.41 and a fifty-two week high of $2.62. The firm has a market capitalization of $63.33 million, a P/E ratio of -0.42 and a beta of 1.03.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Spark Investment Management LLC purchased a new stake in shares of Coherus Oncology during the 2nd quarter worth approximately $25,000. Cetera Investment Advisers bought a new stake in shares of Coherus Oncology in the 1st quarter worth approximately $54,000. The Manufacturers Life Insurance Company purchased a new position in Coherus Oncology in the second quarter valued at approximately $54,000. Dimensional Fund Advisors LP purchased a new position in Coherus Oncology in the first quarter valued at approximately $60,000. Finally, Hsbc Holdings PLC purchased a new position in Coherus Oncology in the second quarter valued at approximately $131,000. 72.82% of the stock is owned by institutional investors.
Coherus Oncology Company Profile
Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.
Recommended Stories
- Five stocks we like better than Coherus Oncology
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
